NMS-P730

NMS-P730 is a potent and highly selective small molecule inhibitor of BRAF, specifically targeting the BRAFV600E mutation. Developed by Nerviano Medical Sciences, it belongs to a class of arylpyrazole derivatives. The compound demonstrates low nanomolar affinity for the mutated kinase and shows significant selectivity over wild-type BRAF and other kinases. In preclinical studies, NMS-P730 has shown the ability to inhibit the MAPK signaling pathway and suppress the proliferation of BRAF-mutant cancer cell lines. In vivo models of melanoma (A375 xenografts) have demonstrated potent tumor growth inhibition following oral administration.